---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-25-000004"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:22:17.148542+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Supernus receives FDA approval for ONAPGO as first subcutaneous apomorphine infusion device for Parkinson's

## Summary
- ONAPGO approved for continuous treatment of motor fluctuations in advanced Parkinson's patients not controlled by oral levodopa.
- Phase 3 study: ONAPGO reduced daily OFF time by 2.6 hours vs 0.9 hours placebo (p=0.0114); GOOD ON time increased 2.8 vs 1.1 hours.
- Product will be available in the U.S. in Q2 2025, with a support team including nurse education programs.
- Most common adverse events (≥10%): infusion-site nodule, nausea, somnolence, infusion-site erythema, dyskinesia, headache, insomnia.
- CEO Jack Khattar stated ONAPGO demonstrates Supernus' continued commitment to CNS innovation.

## SEC filing metadata
- accession: 0001356576-25-000004
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000004/0001356576-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000004/supn-20250204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-25-000004
- JSON: https://secwatch.observer/filing/0001356576-25-000004.json
- Plain text: https://secwatch.observer/filing/0001356576-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.